Clinical Trials Browser

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Lung Diseases, Interstitial

Advanced Squamous Non-Small Cell Lung Cancer

Triple Negative Breast Neoplasms

Ovarian Neoplasms

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

Ovarian Neoplasms

Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Squamous Cell

Multiple Myeloma, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Gastric Cancer Peritoneal Metastases

Triple Negative Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

Esophageal Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

PDAC - Pancreatic Ductal Adenocarcinoma

Stomach Neoplasms

Stage III and IV Ovarian Cancer

Esophageal Neoplasms

Pancreatic Intraductal Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Uterine Cervical Neoplasms

Recurrence, Endometrial Neoplasms

Advanced Esophageal Carcinoma

Thyroid Neoplasms

Squamous Cell Carcinoma of Head and Neck

Solid Tumor Cancer

Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung

Platinum-sensitive Relapsed Ovarian Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Neoplasms, Endometrial Neoplasms

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

Stomach Neoplasms

Advanced Non-squamous Non-small-cell Lung Cancer

Esophageal Neoplasms

Breast Neoplasms

Chemotherapy

Clinical Trials

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

WOLF

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

CECYDE

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

NeoCamre-HN

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

NEO-ITHRAN

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

MIGRANT

SACTION 2501

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

HYPERBOLIC

MRD2START

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

IMMUNOLIFE2

PANORAMIX

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

EF-001

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

KEYPARTNER

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Myeloprotection With Trilaciclib in Pan-cancer Population

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma